191 related articles for article (PubMed ID: 27451086)
1. Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.
Kuti JL; Ghazi IM; Quintiliani R; Shore E; Nicolau DP
Int J Antimicrob Agents; 2016 Sep; 48(3):342-3. PubMed ID: 27451086
[No Abstract] [Full Text] [Related]
2. Ceftolozane-Tazobactam Pharmacokinetics in a Critically Ill Patient on Continuous Venovenous Hemofiltration.
Oliver WD; Heil EL; Gonzales JP; Mehrotra S; Robinett K; Saleeb P; Nicolau DP
Antimicrob Agents Chemother; 2015 Dec; 60(3):1899-901. PubMed ID: 26711770
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of post-surgical osteomyelitis caused by XDR Pseudomonas aeruginosa with ceftolozane/tazobactam monotherapy.
Gentile I; Buonomo AR; Maraolo AE; Scotto R; De Zottis F; Di Renzo G; Borgia G
J Antimicrob Chemother; 2017 Sep; 72(9):2678-2679. PubMed ID: 28575437
[No Abstract] [Full Text] [Related]
4. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
[TBL] [Abstract][Full Text] [Related]
5. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Vickery SB; McClain D; Wargo KA
Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa.
Gelfand MS; Cleveland KO
Clin Infect Dis; 2015 Sep; 61(5):853-5. PubMed ID: 26021991
[No Abstract] [Full Text] [Related]
7. Multidrug-resistant Pseudomonas aeruginosa skin and soft-tissue infection successfully treated with ceftolozane/tazobactam.
Castaldo N; Givone F; Peghin M; Righi E; Sartor A; Bassetti M
J Glob Antimicrob Resist; 2017 Jun; 9():100-102. PubMed ID: 28495526
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of three severe MDR or XDR Pseudomonas aeruginosa infections with ceftolozane/tazobactam.
Xipell M; Bodro M; Marco F; Martínez JA; Soriano A
Future Microbiol; 2017 Nov; 12():1323-1326. PubMed ID: 28980834
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997
[No Abstract] [Full Text] [Related]
10. Successful treatment of MDR Pseudomonas aeruginosa skin and soft-tissue infection with ceftolozane/tazobactam.
Sousa Dominguez A; Perez-Rodríguez MT; Nodar A; Martinez-Lamas L; Perez-Landeiro A; Crespo Casal M
J Antimicrob Chemother; 2017 Apr; 72(4):1262-1263. PubMed ID: 27999042
[No Abstract] [Full Text] [Related]
11. Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.
Hernández-Tejedor A; Merino-Vega CD; Martín-Vivas A; Ruiz de Luna-González R; Delgado-Iribarren A; Gabán-Díez Á; Temprano-Gómez I; de la Calle-Pedrosa N; González-Jiménez AI; Algora-Weber A
Infection; 2017 Feb; 45(1):115-117. PubMed ID: 27670678
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane-tazobactam: A new-generation cephalosporin.
Cluck D; Lewis P; Stayer B; Spivey J; Moorman J
Am J Health Syst Pharm; 2015 Dec; 72(24):2135-46. PubMed ID: 26637512
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes.
Dietl B; Sánchez I; Arcenillas P; Cuchi E; Gómez L; González de Molina FJ; Boix-Palop L; Nicolás J; Calbo E
Int J Antimicrob Agents; 2018 Mar; 51(3):498-502. PubMed ID: 29158144
[TBL] [Abstract][Full Text] [Related]
15. Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.
MacVane SH; Pandey R; Steed LL; Kreiswirth BN; Chen L
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947473
[TBL] [Abstract][Full Text] [Related]
16. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.
Roger C; Cotta MO; Muller L; Wallis SC; Lipman J; Lefrant JY; Roberts JA
Int J Antimicrob Agents; 2017 Aug; 50(2):227-231. PubMed ID: 28689876
[TBL] [Abstract][Full Text] [Related]
17.
Pragsam AK; Kumar DT; Doss CGP; Iyadurai R; Satyendra S; Rodrigues C; Joshi S; Roy I; Chaudhuri BN; Chitnis DS; Tapan D; Veeraraghavan B
Indian J Med Microbiol; 2018; 36(1):127-130. PubMed ID: 29735843
[TBL] [Abstract][Full Text] [Related]
18. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.
Natesan S; Pai MP; Lodise TP
J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Velez Perez AL; Schmidt-Malan SM; Kohner PC; Karau MJ; Greenwood-Quaintance KE; Patel R
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):356-359. PubMed ID: 27130477
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination.
Sucher AJ; Chahine EB; Cogan P; Fete M
Ann Pharmacother; 2015 Sep; 49(9):1046-56. PubMed ID: 26160970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
